Impact of cAMP on the T-cell response to type II collagen

Immunology

Volumn 111, Issue 1, 2004, Pages 35-40

  Ozegbe, Patricia ^a,b   Foey, Andrew D ^a   Ahmed, Salman ^a   Williams, Richard O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMO CYCLIC AMP; CHOLERA TOXIN; COLLAGEN TYPE 2; CYCLIC AMP; FORSKOLIN; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; PROSTAGLANDIN E2; ROLIPRAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTHRITIS; ARTICLE; CELL ACTIVITY; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; LYMPH NODE CELL; MALE; MEASUREMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL; SUPERNATANT; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UPREGULATION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ANIMALS; ANTIGEN-PRESENTING CELLS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CHOLERA TOXIN; COLLAGEN TYPE II; CYCLIC AMP; DINOPROSTONE; ENZYME ACTIVATION; FORSKOLIN; INTERFERON TYPE II; INTERLEUKIN-4; INTERLEUKIN-5; MALE; MICE; MICE, INBRED DBA; MODELS, ANIMAL; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; SECOND MESSENGER SYSTEMS; T-LYMPHOCYTES;

EID: 0345865197     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01768.x     Document Type: Article

References (36)

1. Nyman U, Mussener A, Larsson E, Lorentzen J, Klareskog L. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin Exp Immunol 1997; 108:415-9.
2. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait A-M, Maini RN, Feldmann M. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997; 159:6253-9.
3. Sekut L, Yarnall D, Stimpson SA et al. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 1995; 100:126-32.
4. Francischi JN, Yokoro CM, Poole S, Tafuri WL, Cunha FQ, Teixeira MM. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur J Pharmacol 2000; 399:243-9.
5. Laemont KD, Schaefer CJ, Juneau PL, Schrier DJ. Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats. Int J Immunopharmacol 1999; 21:711-25.
6. Malfait AM, Malik AS, Marinova-Mutafchieva L, Butler DM, Maini RN, Feldmann M. The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. J Immunol 1999; 162:6278-83.
7. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7:563-8.
8. Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol 2001; 167:3182-9.
9. Williams RO. Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum 2002; 46:271-3.
10. Gajewski TF, Schell SR, Fitch FW. Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones. J Immunol 1990; 144:4110-20.
11. Munoz E, Zubiaga AM, Merrow M, Sauter NP, Huber BT. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J Exp Med 1990; 172:95-103.
12. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146:108-13.
13. Crocker IC, Townley RG, Khan MM. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 1996; 31:223-35.
14. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang SK. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997; 282:505-12.
15. Braun CM, Huang SK, Kagey-Sobotka A, Lichtenstein LM, Essayan DM. Co-regulation of antigen-specific T lymphocyte responses by type I and type II cyclic AMP-dependent protein kinases (cAK). Biochem Pharmacol 1998; 56:871-9.
16. Staples KJ, Bergmann M, Tomita K, Houslay MD, McPhee I, Barnes PJ, Giembycz MA, Newton R. Adenosine 3′,5′-cyclic monophosphate (cAMP) -dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol 2001; 167:2074-80.
17. Lacour M, Arrighi JF, Muller KM, Carlberg C, Saurat JH, Hauser C. cAMP up-regulates IL-4 and IL-5 production from activated CD4+ T cells while decreasing IL-2 release and NF-AT induction. Int Immunol 1994; 6:1333-43.
18. Siegel MD, Zhang DH, Ray P, Ray A. Activation of the interleukin-5 promoter by cAMP in murine EL-4 cells requires the GATA-3 and CLE0 elements. J Biol Chem 1995; 270:24548-55.
19. Chen CH, Zhang DH, LaPorte JM, Ray A. Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J Immunol 2000; 165:5597-605.
20. Lee HJ, Takemoto N, Kurata H, Kamogawa Y, Miyatake S, O'Garra A, Arai N. GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med 2000; 192:105-15.
21. Suarez A, Mozo L, Gutierrez C. Generation of CD4(+) CD45RA(+) effector T cells by stimulation in the presence of cyclic adenosine 5′-monophosphate- elevating agents. J Immunol 2002; 169:1159-67.
22. Staples KJ, Bergmann M, Barnes PJ, Newton R. Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action. Biochem Biophys Res Commun 2000; 273:811-15.
23. Miller EJ. Structural studies on cartilage collagen employing limited cleavage and solubilization with pepsin. Biochemistry 1972; 11:4903-9.
24. Sheridan CM, Heist EK, Beals CR, Crabtree GR, Gardner P. Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. J Biol Chem 2002; 25:25.
25. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 2002; 14:1-9.
26. Vang T, Torgersen KM, Sundvold V et al. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 2001; 193:497-507.
27. Feliciello A, Gottesman ME, Avvedimento EV. The biological functions of A-kinase anchor proteins. J Mol Biol 2001; 308:99-114.
28. Michel JJ, Scott JD. AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol 2002; 42:235-57.
29. Schillace RV, Andrews SF, Liberty GA, Davey MP, Carr DW. Identification and characterization of myeloid translocation gene 16b as a novel a kinase anchoring protein in T lymphocytes. J Immunol 2002; 168:1590-9.
30. Williams RO. Cutting Edge: a-kinase anchor proteins are involved in maintaining resting T cells in an inactive state. J Immunol 2002; 168:5392-6.
31. Jaffe BM, Behrman HR, Parker CW. Radioimmunoassay measurement of prostaglandins E, A, and F in human plasma. J Clin Invest 1973; 52:398-405.
32. Seppala E, Nissila M, Isomaki H, Wuorela H, Vapaatalo H. Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis. Scand J Rheumatol 1990; 19:71-5.
33. Berenbaum MC, Cope WA, Bundick RV. Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Relation to immunosuppression induced by trauma. Clin Exp Immunol 1976; 26:534-41.
34. Kambayashi T, Wallin RP, Ljunggren HG. cAMP-elevating agents suppress dendritic cell function. J Leukoc Biol 2001; 70:903-10.
35. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181:775-9.
36. Delgado M, Leceta J, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol 1999; 163:3629-35.